Kamel Abraham, MD in Springfield, OH - Pain Medicine

Kamel Abraham, MD is a Pain Medicine - Pain Medicine physician based in Springfield, Ohio. Kamel Abraham is licensed to practice in Ohio (license number 35054847) and his current practice location is 1117 E Home Rd, Springfield, Ohio. He can be reached at his office (for appointments etc.) via phone at (937) 298-5333.

NPI number for Kamel Abraham is 1891887048 and his current mailing address is 3066 Kettering Blvd, Moraine, Ohio. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1891887048.

Contact Information

	Kamel Abraham, MD
	1117 E Home Rd, Springfield, OH 45503-2725
	(937) 298-5333
	(937) 298-5923

Physician's Profile

Full Name	Kamel Abraham
Gender	Male
Speciality	Pain Medicine - Pain Medicine
Location	1117 E Home Rd, Springfield, Ohio
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1891887048
Provider Enumeration Date: 09/28/2006
Last Update Date: 03/27/2017

Medical Identifiers

Medical identifiers for Kamel Abraham such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1891887048	NPI	-	NPPES
2059776	Medicaid	OH

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207L00000X	Anesthesiology	35054847 (Ohio)	Secondary
208VP0000X	Pain Medicine - Pain Medicine	35054847 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Kamel Abraham is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Kamel Abraham, MD 3066 Kettering Blvd, Moraine, OH 45439-1960 Ph: (937) 342-1619	Kamel Abraham, MD 1117 E Home Rd, Springfield, OH 45503-2725 Ph: (937) 298-5333

News Archive

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

Possible vaccine to protect newborns from fatal bacteria Group B Streptococcus

Microbiologists from the University of Bradford believe they may be closer to developing a vaccine that can protect newborn babies from being infected by the common and potentially fatal bacteria Group B Streptococcus.

BioTime enters MTA with UC to make research-grade hES cell lines

BioTime, Inc. today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM).

Bioluminescence part of new imaging technique

CNRS scientists in collaboration have developed a new technique for the in vivo imaging of neuronal function using bioluminescence, based on a GFP-aequorin fusion protein.

Efforts to correct false beliefs about health care reform may backfire

Efforts to correct false beliefs about health care reform may backfire, depending on individuals' political views and level of knowledge, suggests a study in the February issue of Medical Care.

Kamel Abraham, MD - Pain Medicine in Springfield, OH